Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.1528
-0.0129 (-7.79%)
Oct 28, 2026, 2:32 PM EDT - Market open
Silexion Therapeutics Employees
As of December 31, 2025, Silexion Therapeutics had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes Silexion Therapeutics the 39,382nd largest employer in the world and 5,817th in the United States.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$997,000
Market Cap
849.61K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 13 | 1 |
| Dec 31, 2024 | 14 | - | - | 11 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Jaguar Health | 47 |
| Virax Biolabs Group | 26 |
| Genprex | 13 |
| Lunai Bioworks | 12 |
| Artelo Biosciences | 7 |
| SciSparc | 3 |
| Endovia Health Sciences | 2 |
SLXN News
- 4 weeks ago - Silexion announces first patient dosed in Phase 2/3 trial of SIL204 - TheFly
- 4 weeks ago - Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - Silexion Therapeutics Announces Exercise of Warrants - GlobeNewsWire
- 4 weeks ago - Silexion Therapeutics reports preclinical findings for SIL204 - TheFly
- 4 weeks ago - Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers - GlobeNewsWire
- 7 weeks ago - Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewsWire
- 2 months ago - Silexion Therapeutics prices $2.5M public offering at $0.65 per share - TheFly
- 2 months ago - Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire